Only peer-reviewed journal publications underlying the AblaView® platform are listed publicly. Conference materials are shared with qualified partners on request.
The device presented is under preclinical/clinical investigation. It is not FDA approved nor CE labelled.
Terricabras M, Verma A, Martins R, et al. Europace 2025;27(2):euaf009.
Ten-patient first-in-human study of unipolar PFA delivered with PS-OCR-integrated catheter guidance. 100% specificity for predicting durable lesions at three-month electroanatomic remap. No device-related serious adverse events, no hemolysis, no neurovascular complications.
Terricabras M, et al. Circulation 2024.
Bench and large-animal validation of PS-OCR-derived birefringence as a real-time correlate of irreversible cardiac muscle injury. Established the histological ground truth that underpins the AblaView Clinical AI Engine.
The full evidence package, including preclinical reports, FIM data summaries, study protocol and conference materials, is available to qualified healthcare professionals and research partners on request under non-disclosure, subject to publisher and regulatory compliance review.